Published on


Toxicology – Trimethobenzamide


Description

Trimethobenzamide, commonly known by the brand name Tigan, is an antiemetic medication.


Forms and Uses

Trimethobenzamide is used to control nausea and vomiting.

A usual adult dose is:

250 mg orally three times daily

or

200 mg intramuscularly or rectally every 6–8 hours.


Toxic Dose

The toxic dose of trimethobenzamide is not well established.

In general, relatively large amounts would need to be ingested before significant toxicity would be expected.


Pathophysiology

Trimethobenzamide is a nonphenothiazine antiemetic that acts primarily by depressing the chemoreceptor trigger zone.

Most toxic effects are related to anticholinergic activity.

In some patients, evidence of α-adrenergic blockade may also be present.


Epidemiology

Trimethobenzamide poisoning is uncommon.

When poisoning does occur, clinical effects are usually mild.


Causes

Most significant overdoses are intentional.

In very young children, inappropriate exposure may raise concern for neglect or abuse.

In older children, adolescents, or adults, intentional self-poisoning should be considered when appropriate.


Pregnancy and Lactation

The historical FDA classification listed trimethobenzamide as Pregnancy Category C.

Animal studies demonstrated adverse fetal effects, while adequate controlled human studies were not available.


Differential Diagnosis

Other substances that may produce anticholinergic findings include:

Atropine

Scopolamine

and

Antihistamines


Clinical Features

Acute overdose primarily produces anticholinergic manifestations.

More severe poisoning may involve CNS depression, cardiovascular instability, seizures, muscle weakness, or dysrhythmias.


Vital Signs

Possible abnormalities include:

Tachycardia

Hyperthermia

Hypertension

or

Hypotension


HEENT

Patients may develop:

Dry mouth

and

Difficulty swallowing.

Mydriasis is more commonly reported, although miosis may occasionally occur.


Cardiovascular Effects

Hypotension may occur because of peripheral vasodilation.

In very large overdoses, quinidine-like cardiac effects may produce:

Myocardial depression

and

Ventricular dysrhythmias.


Pulmonary Effects

Respiratory depression may occur in severe poisoning, particularly when significant muscle weakness develops.


Gastrointestinal Effects

Vomiting may occur following overdose.


Hepatic Effects

Hepatitis has been reported.


Musculoskeletal Effects

Dystonic reactions may occur.

Very large overdoses may produce significant muscle weakness or paralysis.


Neurologic Effects

CNS depression may progress from:

Somnolence → marked depression of consciousness → coma

Other neurologic manifestations may include:

Tremor

Hallucinations

and

Seizures.


Laboratory Evaluation

Asymptomatic patients may not require extensive laboratory testing.

In symptomatic patients, useful studies may include:

Serum electrolytes

BUN

Creatinine

Glucose

and other investigations directed at alternative causes of altered mental status.


Respiratory Evaluation

Pulse oximetry should be used in symptomatic patients.

Arterial blood gases may be obtained when there is concern for significant respiratory depression or impaired oxygenation.


ECG

An ECG should be obtained in significant poisoning, especially when there is concern for conduction abnormalities.

Attention should be given to possible QRS widening.


Screening for Coingestants

In deliberate overdose, acetaminophen and salicylate concentrations may be obtained to identify an occult coingestion.


Treatment

Supportive care is the mainstay of treatment.

The amount ingested, timing of exposure, and possibility of coingested substances should be determined whenever possible.


When to Seek Toxicology Assistance

Poison-center or toxicology consultation is appropriate when:

Severe or persistent toxicity develops

or when:

A coingestant, interaction, or underlying disease complicates the clinical picture.


Referral to a Health-Care Facility

Medical evaluation is appropriate when:

Intentional poisoning is suspected

Symptoms develop

The history is unreliable

or

Important coingestants or underlying illnesses are present.


Admission

Prolonged observation or hospital admission is usually unnecessary in minor exposures.

Admission is appropriate when the patient develops:

CNS depression

or

Significant cardiovascular effects.


Decontamination – Out of Hospital

Vomiting should not be induced.


Decontamination – In Hospital

The historical management approach included gastric lavage in patients presenting within approximately 1 hour after a large ingestion or when severe effects were already present.

A single dose of activated charcoal was also recommended after a substantial recent ingestion.


Antidote

There is no specific antidote for trimethobenzamide poisoning.

Management is supportive and directed toward individual complications.


Seizures

Airway patency should be maintained.

Benzodiazepines are used as initial seizure treatment.

If seizures continue or recur, an additional anticonvulsant such as phenobarbital may be added.


Dystonic Reactions

Dystonic reactions may be treated with:

Diphenhydramine 25–50 mg

given intravenously, intramuscularly, or orally.

Treatment may then be continued orally for several days to reduce the chance of recurrence.


Hypotension

When hypotension is associated with clinically significant bradycardia, atropine may be used.

Initial circulatory support includes:

0.9% saline, approximately 10–20 mL/kg intravenously.

The historical approach also included Trendelenburg positioning and further fluid therapy guided by hemodynamic monitoring.


Vasopressors

If hypotension does not respond adequately to fluids, vasopressor therapy may be required.

Historically, dopamine was recommended at:

2–5 μg/kg/min IV

with upward titration according to response.

Higher doses could be used if necessary, although increasing beyond approximately 20 μg/kg/min was considered unlikely to add significant benefit.

Another vasopressor could be added when hypotension remained refractory.


Patient Monitoring

Symptomatic patients should receive:

Continuous cardiac monitoring

Supplemental oxygen when required

and

IV access.

Vital signs and neurologic status should be reassessed regularly.


Expected Course and Prognosis

Anticholinergic manifestations generally peak within several hours.

In more significant poisoning, symptoms may take 24 hours or longer to resolve completely.

Most patients recover with supportive treatment.


Discharge From the Emergency Department

Asymptomatic patients with stable vital signs may be considered for discharge after:

Appropriate decontamination

Approximately 4–6 hours of observation

and

Psychiatric assessment when indicated.


Discharge From Hospital

Hospitalized patients may be discharged when they have recovered sufficiently to care for themselves and no significant toxic effects remain.

Psychiatric evaluation should be completed when clinically appropriate.


Important Pitfalls

Dystonic reactions may recur after the initial symptoms resolve.

Failure to continue treatment for several days may allow dystonia to return.


Significant CNS depression should not automatically be attributed to trimethobenzamide.

Other toxicologic, metabolic, neurologic, or infectious causes should be considered when the presentation is atypical.


High-Yield Toxicology Pearls

Trimethobenzamide is a nonphenothiazine antiemetic that primarily produces anticholinergic toxicity in overdose.


Typical overdose findings include:

Tachycardia + dry mouth + mydriasis + CNS depression


Other possible manifestations include:

Hyperthermia

hypotension

hallucinations

seizures

dystonia

and, in massive overdose:

ventricular dysrhythmias or muscle paralysis.


There is:

No specific antidote.

Treatment is mainly supportive.


For seizures:

Benzodiazepines first-line

with phenobarbital if needed.


For dystonic reactions:

Diphenhydramine

may be used, with continued treatment for several days to prevent recurrence.


Significant hypotension requires:

IV fluids

and, when necessary:

vasopressor support.


Symptomatic patients should receive:

Cardiac monitoring + oxygenation assessment + IV access.


Most toxicity resolves within hours, although significant anticholinergic effects may persist for 24 hours or longer.


The most important practical warning is:

In trimethobenzamide overdose, supportive care is usually sufficient, but severe CNS depression, seizures, hypotension, or ventricular dysrhythmia indicate a much more serious exposure.



Image description
0 Comments